Burlington Stores Inc vs Sana Biotechnology Inc — how do they compare? Burlington Stores Inc trades at $344.28 (market cap $21.04B), while Sana Biotechnology Inc trades at $3.55 (market cap $994.89M). The key difference: Burlington Stores Inc is far larger — about 21.1× Sana Biotechnology Inc's market cap, and Burlington Stores Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| BURL | SANA | |
|---|---|---|
Market Cap | $21.04B | $994.89M |
Sector | Consumer Cyclical | Health |
52-Week High | $347.82 | $5.92 |
52-Week Low | $242.43 | $2.68 |
Enterprise Value | $26.17B | $969.08M |
Signals from Pluang's Aura AI — not financial advice
Burlington Stores (BURL) trades at $327.59, showing minimal daily movement with a slight 0.04% decline. The stock maintains strong bullish technical signals with moving averages supporting upward momentum, though RSI levels suggest potential overbought conditions. Fundamentally, the company demonstrates robust performance with consistent earnings beats, including Q1 2026 EPS of $2.01 exceeding expectations of $1.80. Revenue growth continues with 2025 reaching $10.63 billion and projected increase to $11.9 billion in 2026.
Outlook remains positive with 94% analyst buy ratings and $364.40 consensus price target representing 11% upside. Key opportunities include margin expansion and store productivity improvements, while risks involve competitive retail pressures and inventory management challenges. The company's strong cash flow generation and debt-to-asset ratio of 19.5% provide financial stability for continued growth initiatives.
SANA Biotechnology trades at $3.64, down 5.45% over 24 hours, with a bullish technical signal and strong analyst support (81.82% buy ratings). Recent news highlights clinical progress, including NEJM publications and conference presentations, but financials show significant losses with a net income of -$244.17M in 2025 and negative cash flows.
The outlook is mixed: strong scientific momentum and Wall Street optimism contrast with deep financial losses and high burn rate. Key risks include funding needs and clinical trial outcomes, while potential upside hinges on successful product development and partnerships.
Trailing returns across standard periods
Latest headlines on both assets
Burlington is a leading off-price retailer in the US, offering branded apparel, footwear, and home goods at significant discounts. It operates hundreds of stores focused on delivering high-quality products at great value.
Read more on BURL →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →